

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

TEVA PHARMACEUTICALS USA, INC.,)	REDACTED PUBLIC
TEVA PHARMACEUTICAL INDUSTRIES LTD.,)	VERSION
and NOVOPHARM, LTD.,)	
)	
Counterclaim Plaintiffs,)	C.A. No. 02-1512 (SLR)
v.)	
)	CONSOLIDATED
ABBOTT LABORATORIES,)	
FOURNIER INDUSTRIE ET SANTÉ, and)	
LABORATOIRES FOURNIER S.A.,)	
Counterclaim Defendants.)	
)	
IMPAX LABORATORIES, INC.,)	
)	
Counterclaim Plaintiff,)	C.A. No. 03-120 (SLR)
v.)	
)	CONSOLIDATED
ABBOTT LABORATORIES,)	
FOURNIER INDUSTRIE ET SANTÉ, and)	
LABORATOIRES FOURNIER S.A.,)	
)	
Counterclaim Defendants.)	
)	
IN RE TRICOR DIRECT PURCHASER)	C.A. No. 05-340 (SLR)
ANTITRUST LITIGATION)	
)	CONSOLIDATED
THIS DOCUMENT RELATES TO:)	
ALL ACTIONS)	
)	
IN RE TRICOR INDIRECT PURCHASER)	C.A. No. 05-360 (SLR)
ANTITRUST LITIGATION)	
)	CONSOLIDATED
THIS DOCUMENT RELATES TO:)	
ALL ACTIONS)	

**DEFENDANTS' JOINT APPENDIX
IN SUPPORT OF SUMMARY JUDGMENT MOTIONS**

VOLUME II OF III

MORRIS, NICHOLS, ARSHT & TUNNELL LLP
Mary B. Graham (#2256)
James W. Parrett, Jr. (#4292)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
mgraham@mnat.com
jparrett@mnat.com

OF COUNSEL:

William F. Cavanaugh, Jr.
Thomas W. Pippert
Chad J. Peterman
Alexis Deise
PATTERSON, BELKNAP, WEBB & TYLER LLP
1133 Avenue of the Americas
New York, NY 10036-6710
(212) 336-2000

Attorneys for Defendant Abbott Laboratories

Dated: May 5, 2008
Redacted Filing Date: May 13, 2008

RICHARDS, LAYTON & FINGER, P.A.
Frederick L. Cottrell, III (#2555)
Anne Shea Gaza (#4093)
One Rodney Square
P.O. Box 551
Wilmington, DE 19899
(302) 651-7700
cottrell@rlf.com
gaza@rlf.com

OF COUNSEL:

William Baer
James Cooper
Anne P. Davis
ARNOLD & PORTER LLP
555 12th Street, N.W.
Washington, DC 20004
(202) 942-5000

Timothy C. Bickham
STEPTOE & JOHNSON LLP
1330 Connecticut Avenue, N.W.
Washington, DC 20036-1795
(202) 429-5517

*Attorneys for Fournier Industrie Et Santé and
Laboratoires Fournier, S.A.*

DEFENDANTS' JOINT APPENDIX
TABLE OF CONTENTS

DOCUMENT DESCRIPTION	APPENDIX PAGES
DEPOSITION TRANSCRIPTS/EXHIBITS	
Dr. Loyd V. Allen Deposition Transcript, December 12, 2001	DJA-1 to DJA-4
Pierre Diebolt Deposition Transcript, June 8, 2004	DJA-5 to DJA-7.003
Edward Grieff Deposition Transcript, June 25, 2004	DJA-7.004 to DJA-7.008
Dr. Gordon Amidon Deposition Transcript, November 18, 2004	DJA-8 to DJA-9
Dr. Loyd V. Allen Deposition Transcript, November 23, 2004	DJA-10 to DJA-12
James McNeil Deposition Transcript, December 22, 2004	DJA-12.001 to DJA-12.006
Philippe Reginault Deposition Transcript, October 24, 2006	DJA-13 to DJA-22
Philippe Reginault Deposition Exhibit 1, October 24, 2006	DJA-23 to DJA-28
Philippe Reginault Deposition Exhibit 4, October 24, 2006	DJA-29 to DJA-32
Philippe Reginault Deposition Exhibit 8, October 24, 2006	DJA-33 to DJA-46
Philippe Reginault Deposition Exhibit 25, October 24, 2006	DJA-47 to DJA-52
Pascale Blouquin, Deposition Transcript, November 30, 2006	DJA-52.001-52.004
Dr. Peter Jones Deposition Transcript, November 28, 2007	DJA-53 to DJA-57
Keith B. Leffler Deposition Transcript, December 7, 2007	DJA-58 to DJA-80
Dr. Sander J. Robins Deposition Transcript, December 19, 2007	DJA-81 to DJA-97
Iain Cockburn Deposition Transcript, January 9, 2008	DJA-98 to DJA-106
Dr. Loyd V. Allen Deposition Transcript, January 10, 2008	DJA-107 to DJA-108
Dr. Stephen P. Schondelmeyer Deposition Transcript, January 24, 2008	DJA-109 to DJA-118

DOCUMENT DESCRIPTION	APPENDIX PAGES
Dr. Gordon Amidon Deposition Transcript, January 29, 2008	DJA-119 to DJA-126
Charles L. King III Deposition Transcript, January 29, 2008	DJA-127 to DJA-136
Arthur Schwartzbard Deposition Transcript, February 12, 2008	DJA-137 to DJA-148
Dr. Hal J. Singer Deposition Transcript, February 21, 2008	DJA-149 to DJA-158
Dr. Richard Grimm Deposition Transcript, March 4, 2008	DJA-159 to DJA-168
Dr. Rodolfo Soto Deposition Transcript, March 12, 2008	DJA-169 to DJA-196
Dr. Jeffrey J. Leitzinger Deposition Transcript, March 13, 2008	DJA-197 to DJA-212
DISCOVERY DOCUMENTS	
2005 Marketing Plan (Abbott_Tricor0000007- Abbott_Tricor0000062)	DJA-213 to DJA-268
Pharmaceutical Products Division Cardiology Franchise Summary 2004 Plan (Abbott_Tricor00000111- Abbott_Tricor00000117)	DJA-269 to DJA-275
TriCor 2003 Marketing Plan (Abbott_Tricor00013709, Abbott_Tricor00013743, Abbott_Tricor00013794)	DJA-276 to DJA-278
TriCor '03 Plan (Abbott_Tricor00013965- Abbott_Tricor00014049)	DJA-279 to DJA-363
2006 Strategic Marketing Plan (Abbott_Tricor00056920- Abbott_Tricor00056957)	DJA-364 to DJA-401
Section VI Bioavailability/Bioequivalence (Continued) IABII002617- IABII002619	DJA-402 to DJA-404
Data Summary; In-Process Control in Manufacturing the Biobatch of Fenofibrate Tablets, 100 mg (Lot #R02015) (IABII003278)	DJA-405
Section VII Components and Composition (Continued) IABII014506	DJA-406
In-Process Control in Manufacturing the Biobatch of Fenofibrate Tablets, 54 mg IABII014666	DJA-407

DOCUMENT DESCRIPTION	APPENDIX PAGES
Teva ANDA Application excerpt	DJA-408 to DJA-409
Lofibra Marketing Communications Plan Teva (Teva-TriCor044141- Teva-TriCor044165)	DJA-410 to DJA-434
Convention Report (Teva-TriCor046652-Teva-TriCor46653)	DJA-435 to DJA-436
Lofibra Training Manual (Teva-TriCor083807, Teva-TriCor083859- Teva-TriCor083886)	DJA-437 to DJA-465
REPORTS AND DECLARATIONS	
Expert Statement of Dr. Arthur H. Goldberg in Rebuttal to the Expert Report of Dr. Loyd V. Allen, Jr., October 31, 2001	DJA-466 to DJA-471
Expert Report of Dr. Arthur H. Goldberg, February 15, 2002	DJA-472 to DJA-475
Expert Report of Dr. Loyd V. Allen, Jr., August 26, 2004	DJA-476 to DJA-480
Expert Report of Dr. Stephen R. Byrn, August 27, 2004	DJA-481 to DJA-578
Rebuttal Expert Report of Dr. Gordon Amidon, October 15, 2004	DJA-579 to DJA- 617
Expert Report of Dr. Robert O. Williams III, October 15, 2004	DJA-618 to DJA-651
Declaration of Dr. Robert O. Williams III, January 18, 2005	DJA-652 to DJA-656
Supplemental Expert Report of Dr. Stephen R. Byrn, May 27, 2005	DJA-657 to DJA-667
Declaration of Michael A. Jones, August 16, 2006	DJA-668 to DJA-681
Expert Report of Dr. Edmund Elder, December 14, 2006	DJA-682 to DJA-684
Expert Report of Professor Iain M. Cockburn, December 15, 2006	DJA-685 to DJA-731
Expert Report of Gerhard Levy Relating to the Antitrust Case	DJA-732 to DJA-733
Expert Report of Dr. Gregory K. Leonard, December 15, 2006	DJA-734 to DJA-738
Expert Report of Richard H. Grimm, M.D., M.P.H., P.H.D. on behalf of End Payor Plaintiffs and Pacificare, December 15, 2006	DJA-739 to DJA-747

DOCUMENT DESCRIPTION	APPENDIX PAGES
Expert Report of Jeffrey J. Leitzinger, PH.D, December 15, 2006	DJA-748 to DJA-774
Expert Report of Keith B. Leffler in In Re Tricor Direct Purchaser Antitrust Litigation, December 15, 2006	DJA-775 to DJA-793
Declaration of Charles King III Concerning Liability and Product Market Definition, December 15, 2006	DJA-794 to DJA-814
Declaration of Charles King III Concerning Damages, December 15, 20062006 Physicians' Desk Reference (60 th ed. 2002) Zetia	DJA-815 to DJA-820
Expert Report of Gerhard Levy Relating to the Antitrust Case, December 15, 2006	DJA-821 to DJA-824
Expert Report of Stephen W. Schondelmeyer, Pharm.D., PH.D., December 15, 2006	DJA-825 to DJA-842
Expert Report of Dr. Arthur Schawrtzbard, M.D., F.A.C.C., January 16, 2007	DJA-843 to DJA-846
Expert Report of Dr. Peter Howard Jones, April 17, 2007	DJA-847 to DJA-859
Expert Report of Dr. Gordon Amidon, April 18, 2007	DJA-860 to DJA-875
Expert Report of Dr. Stephen R. Byrn, April 18, 2007	DJA-877 to DJA-907
Expert Report of Dr. Arthur H. Goldberg, April 18, 2007	DJA-908 to DJA-926
Expert Report of Dr. James McGinty, April 18, 2007	DJA-927 to DJA-942
Expert Report of Dr. Robert O. Williams, III, April 18, 2007	DJA-943 to DJA-953
Expert Report of Richard J. Gilbert, PH.D, June 29, 2007	DJA-954 to DJA-990
Expert Report of Margaret E. Guerin-Calvert, June 29, 2007	DJA-991 to DJA-1006
Expert Report of Richard J. Gilbert, PH.D, June 29, 2007	DJA-1007 to DJA-1036
Expert Report of Sander J. Robins, M.D., July 13, 2007	DJA-1037 to DJA-1046
Expert Report of Rodolfo Soto, M.D., July 20, 2007	DJA-1047 to DJA-1050

DOCUMENT DESCRIPTION	APPENDIX PAGES
Reply Expert Report of Stanley A. Kaplan, Ph.D., August 10, 2007	DJA-1051 to DJA-1053
Surrebuttal of Charles King III Concerning Liability and Product Market Definition, October 5, 2007	DJA-1054 to DJA-1067
Rebuttal Expert Report of Professor Iain M. Cockburn, October 8, 2007	DJA-1068 to DJA-1087
Rebuttal Expert Report of Jeffrey J. Leitzinger, PH.D., October 8, 2007	DJA-1088 to DJA-1094
Expert Report of Keith B. Leffler, October, 8, 2007	DJA-1095 to DJA-1105
Supplemental Expert Report of Richard J. Gilbert, PH.D, March 28, 2008	DJA-1106 to DJA-1118
LEGAL FILINGS	
Defendant's Memorandum of Law in Support of Motion for Partial Summary Judgment of Non-Infringement, US Dist. Court for the N. District of Illinois Eastern Division, April 23, 2002	DJA-1119 to DJA-1122
Declaration of Philippe Reginault, Deposition Exhibit 25	DJA-1123 to DJA-1128
Declaration of Charles King III, Concerning Damages, December 15, 2006	DJA-1129 to DJA-1134
Declaration of Charles King III, Concerning Liability and Product Market Definition, December 15, 2006	DJA-1135 to DJA-1155
MISCELLANEOUS	
Webster's Third New International Dictionary of the English Language Unabridged	DJA-1156 to DJA-1157
IMS Business Watch Article "1999 In Review" May 2000	DJA-1158 to DJA-1168
ATP III Executive Summary May 2001	DJA-1169 to DJA-1208
2002 Physicians' Desk Reference (56 th ed. 2002)	DJA-1209 to DJA-1209
2002 Physicians' Desk Reference (56 th ed. 2002)	DJA-1210 to DJA-1214

DOCUMENT DESCRIPTION	APPENDIX PAGES
Teva Internal Document re Formula Comparison, June 14, 2002	DJA-1215 to DJA-1238
Kurt Nielsen Letter, August 21, 2002	DJA-1239 to DJA-1247
Charles Wolfe Letter, December 9, 2002	DJA-1248 to DJA-1264
Mark Shaw Letter, January 28, 2003	DJA-1265 to DJA-1279
Declaration of Philippe Reginault, June 13, 2003	DJA-1280 to DJA-1285
Kurt Nielsen Letter, July 16, 2003	DJA-1286 to DJA-1293
Mark Shaw Letter, August 8, 2003	DJA-1294 to DJA-1300
Mark Shaw Letter, November 28, 2003	DJA-1301 to DJA-1320
Kurt Nielsen Letter, December 12, 2003	DJA-1321 to DJA-1329
Blouquin Declaration, February 17, 2005	DJA-1330 to DJA-1334
2006 Physicians' Desk Reference (60 th ed. 2002) Crestor	DJA-1335 to DJA-1340
2006 Physicians' Desk Reference (60 th ed. 2002) Pravachol	DJA-1341 to DJA-1346
2006 Physicians' Desk Reference (60 th ed. 2002) Advicor	DJA-1347 to DJA-1352
2006 Physicians' Desk Reference (60 th ed. 2002) Niaspan	DJA-1353 to DJA-1357
2006 Physicians' Desk Reference (60 th ed. 2002) Zocor	DJA-1358 to DJA-1364
2006 Physicians' Desk Reference (60 th ed. 2002) Vytorin	DJA-1365 to DJA-1369
2006 Physicians' Desk Reference (60 th ed. 2002) Zetia	DJA-1370 to DJA-1376
2006 Physicians' Desk Reference (60 th ed. 2002) Lipitor	DJA-1377 to DJA-1380
2006 Physicians' Desk Reference (60 th ed. 2002) Lescol	DJA-1381 to DJA-1386
2006 Physicians' Desk Reference (60 th ed. 2002) Omacor	DJA-1386 to DJA-1387

DOCUMENT DESCRIPTION	APPENDIX PAGES
Tricor Label 48 mg and 145 mg	DJA-1387.001 to DJA-1387.012
2007 Standards of Medical Care in Diabetes	DJA-1388 to DJA-1477
2007 Washington Manual of Medical Therapeutics - WMMT - Dyslipidemia	DJA-1478 to DJA-1489
PATENTS	
United States Patent 4,895,726	DJA-1490 to DJA-1494
United States Patent 6,074,670	DJA-1495 to DJA-1503
United States Patent 6,277,405	DJA-1504 to DJA-1512
United States Patent 6,589,522	DJA-1513 to DJA-1521
United States Patent 6,652,881	DJA-1522 to DJA-1530

2316401

REDACTED
IN ITS
ENTIRETY

CERTIFICATE OF SERVICE

The undersigned hereby certifies that on May 13, 2008, the foregoing was caused to be electronically filed with the Clerk of the Court using CM/ECF which will send electronic notification of such filing to all registered participants.

In addition, the undersigned hereby certifies that true and correct copies of the foregoing were caused to be served via electronic mail on May 13, 2008 upon the following parties:

REPRESENTING DIRECT PURCHASER CLASS
PLAINTIFFS (LOUISIANA WHOLESALE,
ROCHESTER DRUG, MEIJER)

(C.A. 05-340)

Jeffrey S. Goddess
jgoddess@rmgglaw.com
Bruce E. Gerstein
bgerstein@garwingerstein.com
Barry S. Taus
btaus@garwingerstein.com
Adam M. Steinfeld
asteinfeld@garwingerstein.com
Daniel Berger
danberger@bm.net
Eric L. Cramer
ecramer@bm.net
Peter Kohn
pkohn@bm.net
Linda P. Nussbaum
lnussbaum@kaplanfox.com
Stuart Des Roches
stuart@odrlaw.com

REPRESENTING WALGREEN, ECKERD, KROGER, MAXI

(C.A. 05-340)

Elizabeth M. McGeever
emmgeever@prickett.com
Scott E. Perwin
sperwin@kennynachwalter.com

REPRESENTING CVS, RITE AID

(C.A. 05-340)

Elizabeth M. McGeever
emmgeever@prickett.com
Joseph T. Lukens
jlukens@hangley.com
Steve D. Shadowen
sshadowen@hangley.com

REPRESENTING AMERICAN SALES COMPANY INC.
(C.A. 05-340)

Elizabeth M. McGeever
emmgeever@prickett.com
Scott E. Perwin
sperwin@kennynachwalter.com

REPRESENTING INDIRECT PURCHASER
CLASS PLAINTIFFS
(C.A. 05-360)

A. Zachary Naylor
Pamela S. Tikellis
Thomas M. Sobol
Patrick E. Cafferty
Jeffrey L. Kodroff
Bernard J. Persky
Mike Gottsch
Brian Clobes
Michael Tarringer
Tim Fraser
David Nalven
Greg Matthews
Christopher McDonald
Kellie Safar
Theodore M. Lieverman
Pat Howard
tricor@chimicles.com

REPRESENTING PACIFICARE
(C.A. 05-360)

Jonathan L. Parshall
jonp@msllaw.com
William Christopher Carmody
bcarmody@susmangodfrey.com
John Turner
jturner@susmangodfrey.com
Shawn Rabin
srabin@susmangodfrey.com
Justin Nelson
jnelson@susmangodfrey.com
Ken Zylstra
zylstra@verizon.net
Mark Sandman
mms@rawlingsandassociates.com
Jeffrey Swann
js5@rawlingsandassociates.com

REPRESENTING TEVA PHARMACEUTICALS
(C.A. 02-1512)

Josy W. Ingersoll
Karen E. Keller
Bruce M. Gagala
Christopher T. Holding
Ken Cohen
Elaine Blais
tricor@yest.com

REPRESENTING IMPAX LABORATORIES
(C.A. 03-120)

Mary Matterer
mmatterer@morrisjames.com
Asim Bhansali
abhangsali@kvn.com

REPRESENTING FOURNIER
(ALL CASES)

Frederick L. Cottrell, III
Anne Shea Gaza
Steven C. Sunshine
Matthew P. Hendrickson
Bradley J. Demuth
Maggie DiMoscato
Timothy C. Bickham
tricor@rlf.com

/s/ James W. Parrett, Jr.

James W. Parrett, Jr. (#4292)

520842